Programmatic management of rifampicin-resistant tuberculosis with standard regimen in Cameroon: a retrospective cohort study

Christelle Genevieve Jouego, Tinne Gils, Alberto Piubello, Vincent Mbassa, Albert Kuate, Annie Ngono, Edwige Belinga, Antoine Etoundi, Alphonse Tollo, Danielle Makondi, Emmanuel André, Palmer Masumbe, Lutgarde Lynen, Juergen Noeske, Tom Decroo

Research output: Contribution to journalA1: Web of Science-articlepeer-review

Abstract

Objectives: To describe treatment outcomes for rifampicin-resistant tuberculosis (Rr-TB) started on standard regimen and the frequency of acquired drug resistance in patients treated using the standard treatment regimen (STR) in Cameroon between 2015-2019.Methods: This is a retrospective cohort study. Rr-TB patients were initiated on the STR, including a fluoroquinolone (FQ), a second-line injectable drug (SLI), and companion drugs. In case of resistance to fluoroquinolones (FQr) at baseline, FQ, SLI and ethionamide were replaced by bedaquiline, delamanid, and linezolid in a modified treatment regimen (mTR), FQr-mTR. In case of resistance to SLI (SLIr) at baseline, SLI was replaced by linezolid (LZD), SLIr-mTR. Logistic regression and competing risk regression were used to estimate predictors of early (first eight weeks) mortality and overall mortality, respectively.Results: Of 709 patients started on a standard regimen, treatment success occurred in 84.7% (587/693), 72.7% (8/11) and 100% (10/10) of patients treated with STR, FQr-mTR and SLIr-mTR as final regimens, respectively. Three (0.6%) patients acquired FQr during treatment. Early mortality occurred in 4.1% (29/709) and was associated with being HIV positive, male sex and being underweight. Overall mortality was associated with missing drug-susceptibility testing results at baseline, being HIV positive, age > 40 and male sex. Conclusion: Programmatic management of Rr-TB, with additional second-line drug resistance treated with mTR, resulted in excellent treatment outcomes.(c) 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Original languageEnglish
JournalInternational Journal of Infectious Diseases
Volume124
Pages (from-to)81-88
Number of pages8
ISSN1201-9712
DOIs
Publication statusPublished - 2022

Keywords

  • Rr-TB
  • Fluoroquinolone and second -line injectable
  • resistance
  • Standard regimen
  • Cameroon
  • Standard treatment

Cite this